


Les antibiotiques, encore
automatiques?

Plan national

- Plan National d'alerte 2011-2016
- <http://www.plan-antibiotiques.sante.gouv.fr>
 - Améliorer l'efficacité de la prise en charge
 - Préserver l'efficacité des antibiotiques
 - Promouvoir la recherche
- Objectif : -25% de consommation en 2016


- Diminution de 12,5% entre 2000 et 2012
 - Baisse notable jusqu'en 2005...

Trend of the consumption of antimicrobials in ATC group J01 (antibacterials for systemic use) in the community (primary care sector) in France from 1997 to 2013




- Diminution de 12,5% entre 2000 et 2012
 - Baisse notable jusqu'en 2005...

Trend of the consumption of antimicrobials in ATC group J01 (antibacterials for systemic use) in the community (primary care sector) in France from 1997 to 2013




- Diminution de 12,5% entre 2000 et 2012
 - Baisse notable jusqu'en 2005...
 - Tendance à la hausse depuis!

Trend of the consumption of antimicrobials in ATC group J01 (antibacterials for systemic use) in the community (primary care sector) in France from 1997 to 2013




Consommation communautaire 2013



Répartition par classe

Distribution of antimicrobial consumption of Antibacterials For Systemic Use (ATC group J01) in the community (primary care sector) in France, reporting year 2013



Résistances

- Pneumocoques (en ville)
 - Env. 0% en 1980
 - 42% en 2002
 - 24% en 2011


Résistances

- Pneumocoques (en ville)
 - Env. 0% en 1980
 - 42% en 2002
 - 24% en 2011
 - 43% en 2016?


Résistances

- Pneumocoques (en ville)
 - Env. 0% en 1980
 - 42% en 2002
 - 24% en 2011
 - 43% en 2016?
- EBLSE
 - En forte augmentation dans les établissements
 - E. coli prédominant

Pneumocoque / macrolides



E. coli (R+I) C3G



Utilisation appropriée

- Tests rapides d'orientation diagnostique
 - Eviter prescription inutile, savoir attendre 48h
- Caractéristiques du patient
 - Age, poids, fonction rénale hépatique, grossesse et allaitement
 - Identifier les patients à risque de complications
- Spectre le plus étroit possible
- Durée la plus courte possible
- Eviter la prescription d'un même antibiotique (ou même classe) dans les 3 mois


Pas de prescription automatique

- Rhinopharyngite aiguë
- Sinusite maxillaire adulte / enfant
- OMA enfant > 2 ans
- OMA congestive et séromuqueuse
- Otite externe
- Bronchite aiguë de l'adulte sain
- Exacerbation aiguë d'une BPCO stade 0 à 3 (sans sécrétions purulentes)
- Bronchiolite sans signe d'OMA associée


3 antibiotiques à surveiller

- Amoxicilline-acide clavulanique
- Céphalosporines
 - Prise orale, C3G, ceftriaxone
- Fluoroquinolones
 - Ne pas réitérer dans les 6 mois après une infection urinaire
 - Ne pas réitérer dans les 3 mois après une infection respiratoire


Association pénicilline inhib. Beta lactamase




Trend of the consumption of antimicrobials in ATC group J01CR (combinations of penicillins, incl. beta-lactamase inhibitors) in the community (primary care sector) in France from 1997 to 2013




C3G




Trend of the consumption of antimicrobials in ATC group J01DD (third-generation cephalosporins) in the community (primary care sector) in France from 1997 to 2013



fluoroquinolones



Trend of the consumption of antimicrobials in ATC group J01MA (fluoroquinolones) in the community (primary care sector) in France from 1997 to 2013



Country	Consumption					Relative consumption					Broad/narrow		Seasonal variation		
	J01*	J01C	J01D	J01F	J01M	J01CE_%	J01CR_%	J01DD+DE_%	J01MA_%	J01_B/N	J01_SV	J01M_SV	J01_B/N	J01_SV	J01M_SV
Austria	16.26	7.38	1.95	3.59	1.47	5.7%	32.4%	3.9%	9.0%	8.25	32.3%	19.1%	8.25	32.3%	19.1%
Belgium	29.64	16.91	1.53	3.38	2.63	<0.1%	29.8%	<0.1%	8.9%	80.12	34.9%	27.6%	80.12	34.9%	27.6%
Bulgaria	19.91	8.45	2.80	3.35	2.52	1.2%	15.2%	2.9%	12.7%	11.83	-	-	11.83	-	-
Croatia	21.10	11.27	2.99	2.80	1.47	3.7%	35.5%	2.1%	7.0%	7.89	13.6%	3.9%	7.89	13.6%	3.9%
Cyprus**															
Czech Republic	19.00	8.10	1.76	3.74	0.88	10.0%	21.9%	0.3%	4.6%	4.79	20.4%	-0.2%	4.79	20.4%	-0.2%
Denmark	16.40	10.56	0.03	1.84	0.52	27.8%	7.4%	<0.1%	3.1%	0.62	15.2%	5.0%	0.62	15.2%	5.0%
Estonia	11.72	4.49	1.10	2.48	0.89	1.8%	15.0%	<0.1%	7.6%	11.60	36.4%	9.1%	11.60	36.4%	9.1%
Finland	18.35	6.23	2.28	1.28	0.84	6.9%	7.2%	<0.1%	4.6%	0.73	13.7%	5.5%	0.73	13.7%	5.5%
France	30.14	18.43	2.25	3.50	1.84	0.6%	24.3%	5.2%	6.0%	47.64	-	-	47.64	-	-
Germany	15.79	4.83	3.22	2.80	1.42	5.3%	2.8%	2.7%	9.0%	5.66	36.8%	23.2%	5.66	36.8%	23.2%
Greece	32.02	12.56	7.38	7.18	2.06	<0.1%	18.1%	0.3%	6.4%	318.32	-	-	318.32	-	-
Hungary	13.84	6.30	1.76	2.41	1.99	2.0%	33.5%	2.5%	14.3%	29.80	-	-	29.80	-	-
Iceland**	21.85	11.62	0.77	1.71	1.13	9.8%	19.8%	0.4%	5.2%	2.08	9.4%	3.8%	2.08	9.4%	3.8%
Ireland	23.81	13.12	1.36	4.40	0.87	4.5%	29.2%	0.4%	3.7%	5.68	20.1%	5.2%	5.68	20.1%	5.2%
Italy	28.63	16.09	2.48	4.80	3.55	<0.1%	41.2%	7.1%	12.1%	171.64	34.2%	25.9%	171.64	34.2%	25.9%
Latvia	13.50	6.56	0.52	1.73	1.06	0.3%	13.8%	0.3%	7.5%	11.75	-	-	11.75	-	-
Liechtenstein															
Lithuania	18.54	10.64	1.22	2.38	0.96	0.9%	11.5%	<0.1%	4.9%	11.69	-	-	11.69	-	-
Luxembourg	27.67	13.77	3.80	3.95	2.65	<0.1%	32.5%	<0.1%	9.6%	53.42	41.3%	25.2%	53.42	41.3%	25.2%
Malta	23.81	9.49	5.52	3.96	2.93	0.3%	35.5%	1.7%	12.3%	153.27	-	-	153.27	-	-
Netherlands	10.83	4.39	0.04	1.39	0.76	2.9%	15.4%	<0.1%	7.0%	7.84	-	-	7.84	-	-
Norway	16.22	6.55	0.11	1.69	0.54	20.8%	<0.1%	<0.1%	3.3%	0.23	-	-	0.23	-	-

Références

- http://www.sante.gouv.fr/IMG/pdf/plan_antibiotiques_2011-2016_DEFINITIF.pdf
- http://www.has-sante.fr/portail/jcms/c_1723138/fr/principes-generaux-et-conseils-de-prescription-des-antibiotiques-en-premier-recours
- http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-database/Pages/database.aspx
- http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx